

# Pharmacy Pearls

## 2022 Diabetes Updates


**Contributors:** Gina Grasso, PharmD Candidate 2022; Samantha Leistman, PharmD

**Contact:** AHPPPharmacist@urmc.rochester.edu

### Updated Treatment Algorithm for T2DM:

Adapted from: Figure 9.3 in Diabetes Care 2022;45(Suppl. 1).

- Metformin is no longer a “must try” first-line agent.
  - Still an effective first-line option and will likely be appropriate initial treatment for many patients
- Treatment should be individualized based on patient-specific factors.



### Changes to Treatment Recommendations for Heart Failure (HF) and Diabetic Kidney Disease (DKD):

#### SGLT2 Inhibitors:

Now a recommended option for patients with or without DM who have, or are at risk for, any type of heart failure

- Empagliflozin (Jardiance®)
  - [EMPEROR-Reduced](#) and [EMPEROR-Preserved](#) trials
- Dapagliflozin (Farxiga®)
  - [DAPA-HF](#) trial

HF

#### SGLT2 Inhibitors:

- Empagliflozin (Jardiance®) and dapagliflozin (Farxiga®) are preferred agents in DKD
- No longer recommended to discontinue SGLT2-I's in patients with Stage 4 CKD
  - Renal and CV events are still reduced until eGFR < 30 ml/min/1.73m<sup>2</sup>, independent of glucose-lowering effects

#### Finerenone (Kerendia®):

- Non-steroidal, selective mineralocorticoid receptor antagonist (approved in 2021)
- Indicated to reduce the risk of sustained eGFR decline, ESRD, CV death, non-fatal MI, and hospitalization for HF in patients with DKD
- Based on results of the [FIGARO-DKD](#) trial, finerenone is:
  - Recommended for all patients with *albuminuric* DKD
  - Suggested alternative for patients with CKD who *cannot tolerate an SGLT2-I*

DKD

### Now Available: Semglee-yfgn® (insulin glargine-yfgn)

- Once-daily long-acting human insulin analog (100 units/mL)
- In June 2020, the FDA approved Semglee® as a human insulin analog and biosimilar to insulin glargine
  - This NDC was not interchangeable with Lantus®, and is being phased out at pharmacies
- In July 2021, the FDA approved Semglee-yfgn® (insulin glargine-yfgn)
  - These NDCs (**branded Semglee-yfgn® and unbranded insulin glargine-yfgn**) are interchangeable with Lantus®, meaning the pharmacy can substitute these for Lantus® without prescriber approval
- **Unbranded insulin glargine-yfgn is the least expensive product**, but branded Semglee-yfgn®'s list price is still lower compared to Lantus®; *these options will reduce costs for patients and health plans.*